Sugi Predict

Sugi Predict / Compounds / SCHEMBL263877

SCHEMBL263877

SCHEMBL263877

CCOC(=O)N=NC(=O)OCC.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ GAA P10253 2/20 0.45
▸ POLB P06746 1/20 0.45
▸ TSHR P16473 1/20 0.44
▸ CYP3A4 P08684 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ PIN1 Q13526 2/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ ESR1 P03372 1/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ CES2 O00748 1/20 0.39
▸ ACHE P22303 1/20 0.39
▸ CES1 P23141 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4398048 1.00 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2GAAPOLBTSHR
SCHEMBL355901 0.95 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2GAAPOLBTSHR
SCHEMBL28863351 0.92 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2GAAPOLBTSHR
Benzoic Acid SCHEMBL8538257 0.92 TSHR (0.42) ALDH1A1SMN1; SMN2GAAPOLBTSHR
Benzoic Acid SCHEMBL8538259 0.92 TSHR (0.42) ALDH1A1SMN1; SMN2GAAPOLBTSHR
SCHEMBL9452987 0.87 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2GAAPOLBTSHR
SCHEMBL28418300 0.87 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2GAAPOLBTSHR
Toluene SCHEMBL717525 0.83 TSHR (0.48) ALDH1A1SMN1; SMN2GAAPOLBTSHR
SCHEMBL27419996 0.83 ALDH1A1 (0.52) ALDH1A1GAATSHRCYP3A4TDP1
SCHEMBL28359555 0.83 TSHR (0.48) ALDH1A1GAATSHRCYP3A4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114981253-B Process and intermediates for preparing chroman compounds and methods therefor 印度鲁宾有限公司 2024-06-18 — — CN claimed
US-20230140054-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LIMITED (IN) 2023-05-04 — — US claimed
CN-114981253-A Process and intermediates for preparing chroman compounds and methods therefor 印度鲁宾有限公司 2022-08-30 — — CN claimed
WO-2021144814-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LIMITED (IN) 2021-07-22 — — WO claimed
US-20050222083-A1 Thiol-modified hyaluronan ANIKA THERAPEUTICS, INC. (US) 2005-10-06 — — US claimed
EP-1368309-A2 THIOL-MODIFIED HYALURONAN Anika Therapeutics Inc. (US) 2003-12-10 — — EP claimed
US-20020128512-A1 Thiol- modified hyaluronan ANIKA THERAPEUTICS, INC. 2002-09-12 — — US claimed
WO-2002068383-A2 THIOL-MODIFIED HYALURONAN ANIKA THERAPEUTICS, INC. (US) 2002-09-06 — — WO claimed
CN-114981253-B Process and intermediates for preparing chroman compounds and methods therefor 印度鲁宾有限公司 2024-06-18 — — CN disclosed
US-11884678-B2 Method for producing a spirooxindole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-01-30 — — US disclosed
EP-3643706-B1 MODIFIED NUCLEIC ACID MONOMERS AND OLIGONUCLEIC ACID ANALOGUES, WITH HIGH BIOLOGICAL STABILITY AND TARGET GENE SILENCING ACTIVITY, FOR USE IN THERAPY AND DIAGNOSIS OF CANCER AND VIRAL DISEASES EISAI R&D MAN CO LTD (JP) 2023-11-15 — — EP disclosed
CN-110655546-B Sofosbuvir derivative, and preparation method and application thereof 安徽贝克制药股份有限公司 2023-05-16 — — CN disclosed
US-20230140054-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LIMITED (IN) 2023-05-04 — — US disclosed
CN-110857268-B Phenoxy acid compound and medical application thereof 青岛睿森生物科技有限公司 2022-10-04 — — CN disclosed
US-5196426-A CALCIUM INDEPENDENT C AMP PHOSPHODIESTERASE INHIBITOR ANTIDEPRESSANT PFIZER INC. (US) 1993-03-23 — — US disclosed
EP-0503785-A1 1-Biphenylimidazole derivatives, their preparation and their therapeutic use Sankyo Company Limited (JP) 1992-09-16 — — EP disclosed
US-5128358-A Aryl substituted nitrogen heterocyclic antidepressants PFIZER INC. (US) 1992-07-07 — — US disclosed
EP-0358432-A2 1,4-dihydropyridine derivatives TAISHO PHARMACEUTICAL CO. LTD (JP) 1990-03-14 — — EP disclosed
EP-0247725-A2 Calcium independent camp phosphodiestrerase inhibitor antidepressant PFIZER INC. (US) 1987-12-02 — — EP disclosed
WO-1987006576-A1 CALCIUM INDEPENDENT CAMP PHOSPHODIESTERASE INHIBITOR ANTIDEPRESSANT PFIZER INC. (US) 1987-11-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140054-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS CASR, CALCR, RYR1 ALDH1A1 2602/4885SMN1; SMN2 2582/4885GAA 2570/4885
US-11884678-B2 Method for producing a spirooxindole derivative MDM2, TP53, RB1 ALDH1A1 628/4885SMN1; SMN2 4855/4885GAA 3731/4885
US-20020128512-A1 Thiol- modified hyaluronan CD44, UACA, TST ALDH1A1 247/4885SMN1; SMN2 4453/4885GAA 3197/4885
US-20050222083-A1 Thiol-modified hyaluronan CD44, UACA, TST ALDH1A1 247/4885SMN1; SMN2 4453/4885GAA 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.